Jan Hillert, MD, PhD: The Blood-Brain Barrier in Multiple Sclerosis
The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet discussed the evolving understanding of the blood-brain barrier in MS, and what might still be left to uncover.
“In a way, the blood-brain barrier is important, but it isn’t as central to our thinking as it used to be. On the other hand, many of our drugs affect the blood-brain barrier in many ways. Even the first-iteration drugs do that to a certain extent.”
The blood-brain barrier has proven over the years to be an important topic in multiple sclerosis (MS) treatment. Studies have suggested that improvements in the understanding of its molecular mechanism of functioning could, in turn, lead to improvements in the quality of life of patients with MS, with recent literature pointing to calnexin as one possible target.1,2
At
When discussing this topic on-site with NeurologyLive's sister publication AJMC, Hillert shared insight into how the conversation around the blood-brain barrier in MS has evolved with the clinical understanding of it, and what might still be left to uncover.
For more coverage of ECTRIMS 2019,
REFERENCE
1. Ortiz GG, Pacheco-Moisés FP, Macías-Islas MÁ, et al. Role of the blood-brain barrier in multiple sclerosis. Arch Med Res. 2014 Nov;45(8):687-97. doi: 10.1016/j.arcmed.2014.11.013.
2. Jung J, Eggleton P, Robinson A, et al. Calnexin is necessary for T cell transmigration into the central nervous system. JCI Insight. 2018;3(5):e98410. doi: 10.1172/jci.insight.98410.
3. Hillert J. The road not (yet) taken: targeting new pathways of MS pathophysiology. Presented at: ECTRIMS 2019; September 11-13; Stockholm, Sweden. Satellite Symposium 5.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.